Compare AbbVie Inc (ABBV) vs Harley-Davidson Inc (HOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Harley-Davidson Inc — how do they compare? AbbVie Inc trades at $254.05 (market cap $449.91B), while Harley-Davidson Inc trades at $25.39 (market cap $2.73B). The key difference: AbbVie Inc is far larger — about 164.8× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays the higher dividend (2.84%). Which is the better fit depends on your goals.
| ABBV | HOG | |
|---|---|---|
Market Cap | $449.91B | $2.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $31.03 |
52-Week Low | $184.85 | $17.19 |
Enterprise Value | $513.38B | $3.12B |
Dividend Yield | 2.72% | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Harley-Davidson (HOG) trades at $25.89, up 3.73% today, with mixed technical signals showing bullish moving averages but neutral oscillators. Fundamentally, the company faces revenue declines from $5.8B in 2022 to $4.5B in 2025, though valuation ratios remain attractive with P/E of 13.12 and P/B of 0.87. Recent Q1 2026 earnings missed expectations at $0.22 vs. $0.34, but Q2 results are anticipated on July 23, 2026. Positive developments include production returning to the US and cost-cutting initiatives.
The outlook is cautious with analyst consensus at Hold (65.71%) and price target of $23.20 below current price. Risks include ongoing margin pressure, competitive threats, and execution of turnaround plans. Upside potential exists if cost savings and US production boost profitability, but investors should monitor Q2 earnings for confirmation of operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →
